Literature DB >> 15346087

Prevention of restenosis after stenting: the emerging role of inflammation.

Francesco Versaci1, Achille Gaspardone.   

Abstract

Restenosis after stent implantation is mainly caused by neointimal proliferation through the stent struts. Experimental studies indicate a marked activation of inflammatory cells at the site of stent struts, which are likely to play a key role in the process of neointimal proliferation and restenosis. Coronary stenting is a strong inflammatory stimulus and the acute systemic inflammatory response to local inflammation produced by coronary stenting is highly individual and predicts restenosis and event-free survival. The benefit of anti-inflammatory therapy during the periprocedural period and long-term follow-up is dependent on the inflammatory status. Measurement of cytokine and acute phase proteins, such as C-reactive protein, may be important to identify high-risk subjects and develop specific treatment tailored to the individual patient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15346087     DOI: 10.1097/00019501-200409000-00002

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  9 in total

1.  Controlled release of triamcinolone acetonide from polyurethane implantable devices: application for inhibition of inflammatory-angiogenesis.

Authors:  Flávia Carmo Horta Pinto; Armando Da Silva-Cunha Junior; Rodrigo Lambert Oréfice; Eliane Ayres; Silvia Passos Andrade; Luiza Dias C Lima; Sandra A Lima Moura; Gisele Rodrigues Da Silva
Journal:  J Mater Sci Mater Med       Date:  2012-04-01       Impact factor: 3.896

Review 2.  Impact of C-reactive protein on in-stent restenosis: a meta-analysis.

Authors:  Jian-Jun Li; Yi Ren; Ke-Ji Chen; Alan C Yeung; Bo Xu; Xin-Min Ruan; Yue-Jin Yang; Ji-Lin Chen; Run-Lin Gao
Journal:  Tex Heart Inst J       Date:  2010

3.  Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in patients on hemodialysis.

Authors:  Hideki Yano; Shigeo Horinaka; Hiroshi Yagi; Toshihiko Ishimitsu
Journal:  Heart Vessels       Date:  2012-04-22       Impact factor: 2.037

Review 4.  Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation.

Authors:  Louis L Nguyen
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

5.  Endoscopic retrograde cholangiopancreatography in patients with previous acute coronary syndrome.

Authors:  Han-Ra Koh; Chang-Hwan Park; Min-Woo Chung; Seon-Young Park; Young-Joon Hong; Myung-Ho Jeong; Hyun-Soo Kim; Sung-Kyu Choi; Jong-Sun Rew
Journal:  Gut Liver       Date:  2014-11-15       Impact factor: 4.519

Review 6.  The long-term prognostic significance of high-sensitive C-reactive protein to in-stent restenosis.

Authors:  Xinyi Zhu; Yuqi Chen; Li Xiang; Tao You; Yang Jiao; Weiting Xu; Jianchang Chen
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

Review 7.  Analysis of arterial intimal hyperplasia: review and hypothesis.

Authors:  Vladimir M Subbotin
Journal:  Theor Biol Med Model       Date:  2007-10-31       Impact factor: 2.432

8.  The correlation between early complications of percutaneous coronary intervention and high sensitive C-reactive protein.

Authors:  Farshad Roghani; Ali Mehrabi Koushki; Negin Nezarat; Mohammad Saleki
Journal:  ARYA Atheroscler       Date:  2013-06

Review 9.  Drug releasing systems in cardiovascular tissue engineering.

Authors:  Cristiano Spadaccio; Massimo Chello; Marcella Trombetta; Alberto Rainer; Yoshiya Toyoda; Jorge A Genovese
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.